U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07317154) titled 'Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients' on Dec. 01, 2025.
Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Recurrent Respiratory Papillomatosis
Intervention:
BIOLOGICAL: Immunotherapy
Each patient will receive 5 doses autologous immunotherapy intradermally.
Recruitment Status: RECRUITING
Sponsor: Mayo Clinic
Information provided by (Responsible Party): David G. Lott, M.D., Mayo Clinic
Disclaimer: C...